Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 18, 2025Expert Review of Anticancer Therapy

Innovation in next-generation sequencing in non-Small cell lung cancer diagnostics

View Full Paper
Ask AI
Bookmark
Share

Authors

CSClaudia ScimoneLPLucia PalumboRBRoberto Borea

Discussion

Loading...

Member takes

Overview

Molecular biomarker testing improves outcomes in non-small cell lung cancer, suggesting NGS technology enhances diagnostic accuracy.

Key Points

  • Next-generation sequencing technology significantly enhances diagnostic accuracy for non-small cell lung cancer.
  • NGS shows higher sensitivity in detecting alterations in challenging tissue and liquid biopsy samples.
  • Assessment of various NGS platforms indicates improvements in clinical utility and cost-effectiveness of biomarker testing.
  • Innovative approaches like multi-omic evaluation are set to reshape clinical algorithms for NSCLC patients.

Cite This Study

Scimone et al. (2025) studied this question.

synapsesocial.com/papers/68af2eeacf1dd9ea359e6986https://doi.org/10.1080/14737140.2025.2549538
View Full Paper
Ask AI
Bookmark
Share